What is  Postsurgical  treatment plan for  a DCIS / female breast cancer,  Ipsilateral, with comorbidity  thromboembolism , undergone lumpectomy as primary treatment plan followed by APBI(Accelerated partial breast irradiation), with Hormone Receptor Status as ER-positive, Postmenopausal, age 55 .

client = OpenAI(api_key='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')

response = client.chat.completions.create(
  model="ft:gpt-3.5-turbo-1106:personal::8iZdWZNp",
  messages=[
    {"role": "system", "content": "Primary treatment plan options for DCIS / TisN0M0 staged/diagnosed breast cancer."},
    {"role": "user", "content": "What is  Postsurgical  treatment plan for  a DCIS / female breast cancer,  Ipsilateral, with comorbidity  thromboembolism , undergone lumpectomy as primary treatment plan followed by APBI(Accelerated partial breast irradiation), with Hormone Receptor Status as ER-positive, Postmenopausal, age 55 ."}
  ]
)
print(response)



ChatCompletion(id='chatcmpl-8j3Csws14EZDIGFm4nOFnjVqN3ncn',
 choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=
' Endocrine therapy for 5 years is highly recommended for patients who have received breast-conserving therapy and WBRT radiation therapy, 
particularly those with ER-positive DCIS with Postmenopausal patients  and age is less than 60 can be prescribed Tamoxifen or an aromatase inhibitor can be considered.
 The standard dose of Tamoxifen is 20 mg/day for 5 years.
 Low-dose Tamoxifen (5 mg/day for 3 years) is an option if the patient has symptoms on the standard dose or cannot tolerate it.
 There is some advantage to using aromatase inhibitors, 
especially in patients under 60 years of age or those with concerns with comorbidity  thromboembolism.', role='assistant', function_call=None, tool_calls=None))], created=1705747778, model='ft:gpt-3.5-turbo-1106:personal::8iZdWZNp', object='chat.completion', system_fingerprint='fp_2dae0bfd7e', usage=CompletionUsage(completion_tokens=146, prompt_tokens=106, total_tokens=252))


" Endocrine therapy for 5 years is highly recommended for patients who have received breast-conserving therapy and WBRT radiation therapy,
 particularly those with ER-positive DCIS with Postmenopausal patients 
 and age is less than 60 can be prescribed Tamoxifen or an aromatase inhibitor can be considered. 
The standard dose of Tamoxifen is 20 mg/day for 5 years. Low-dose Tamoxifen (5 mg/day for 3 years) is an option if the patient has symptoms on the standard dose or cannot tolerate it. There is some advantage to using aromatase inhibitors,
 especially in patients under 60 years of age or those with concerns with comorbidity  thromboembolism."}]}
---------------------------------------
